Pages
Blogroll
- Blood Pressure Risk Factors
- Electric mobility scooters
- Hair Growth Product Reviews
- Hoveround Wheelchairs
- Medical Scales
- Mortgage modification trial payments
- NBA Basketball Betting
- Nursing career
- Pancreas Cancer
- Prevent Cancer
- Prostate Cancer Treatment Side Effects
- Type 2 Diabetes Mellitus
Categories
- Cancer Risk
- Cells and Organs
- General Information
- Prostate Help Organizations
- UK Prostate Cancer
- Uncategorized
Archives
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
Meta
The latest people to object to the recent decision by the Centers for Medicare & Medicaid Services to open a National Coverage Analysis of the Provenge prostate cancer vaccine happen to be two US Senators. John Kerry and Arlen Specter, Democrats from Massachusetts and Pennsylvania, respectively, wrote an Aug. 20 letter to the agency questioning the rationale for the review and voicing suspicion the move will lead to restricted coverage.
At issue is the extent to which CMS believes coverage is reasonable and necessary. As noted previously, an NCA is uncommon for new drugs, but CMS officials have ranged from silent to vague in explaining their decision. Although marketed for $93,000, price is not supposed to factor into the analysis. Presumably, the undertaking was prompted by regional …
Original post by Pharmalot and software by Elliott Back
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.